REG - Destiny Pharma PLC - Publication of new data for XF-73

Destiny PharmaAnnouncement

31/07/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230731:nRSe7558Ha&default-theme=true

RNS Number : 7558H  Destiny Pharma PLC  31 July 2023

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Publication of new data demonstrates significantly superior efficacy of XF-73
compared to a leading topical antibiotic against MRSA in skin infection models

 

Brighton, United Kingdom - 31 July 2023 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and treat life threatening
infections, today announces the publication of new data
(https://www.dovepress.com/efficacy-of-a-novel-antibacterial-agent-exeporfinium-chloride-xf-73-ag-peer-reviewed-fulltext-article-IDR)
in the journal Infection & Drug Resistance from a study evaluating the
potency of Destiny Pharma's antibacterial drug, XF-73, against
methicillin-resistant Staphylococcus aureus (MRSA) in two, industry-standard,
skin infection models and comparing its efficacy against mupirocin, a leading
topical antibiotic.

 

The publication, entitled, "Efficacy of a Novel Antibacterial Agent
Exeporfinium Chloride, (XF‑73), against Antibiotic-Resistant Bacteria in
Superficial Skin Infection Models" concluded that:

 

·    XF-73 dermal formulation was 100 times more effective at killing MRSA
(USA 300 strain) than the topical antibiotic mupirocin, in two skin infection
models

o Single doses of XF-73 and mupirocin reduced MRSA infection by >3 log(10)
CFU/mL (p<0.0001) and <1 log(10), (p<0.05) respectively, relative to
control (no treatment)

·    XF-73 had significantly greater statistical efficacy than mupirocin
in both MRSA skin infection models, (p<0.0001)

·    Mupirocin had little or no impact on mupirocin resistant-MRSA strains
in the skin infection model, even following 2 doses, whereas XF-73's potency
was not impaired and was equally effective against the mupirocin-resistant
MRSA strains, maintaining a >3 log(10) reduction of this superbug

·    XF-73 further demonstrated its potency by achieving these results at
a concentration of 0.2% (w,w), compared to 2% (w,w) marketed mupirocin
ointment i.e. at 10 times less relative concentration.

 

Destiny Pharma's partner, China Medical System Holdings Limited (CMS) is
developing the XF-73 dermal formulation as a treatment for superficial skin
infections through its relationship with Tianjin Medical University.

 

The global acute bacterial skin and skin structure infections market is
estimated to be valued at US$ 3,466 million in 2022 and is expected to
exhibit a CAGR of 6.0% over the forecast period (2022-2030).(1)

 

Destiny Pharma has cross-reference rights to data generated from the programme
and so retains the option to develop dermal XF-73 products for US, European,
Japanese and other territories outside those held by CMS (mainland China, Hong
Kong Special Administrative Region, Macao Special Administrative Region,
Taiwan Region and other certain Asian countries/regions).

 

This research project was partly funded through a £1.6m collaboration between
Destiny Pharma, Cardiff University, CMS and Tianjin Medical University. The
collaboration was established under the UK-China antimicrobial resistance
(AMR) grant fund set up by Innovate UK and the Department of Health with the
Chinese Ministry of Science and Technology.

 

Dr Bill Love, Chief Scientific Officer of Destiny Pharma, said: "This dataset
is compelling and demonstrates clear and significant advantages for XF-73 over
one of the world's leading topical antibiotics, mupirocin. It adds further
impetus for the clinical development of XF-73 to treat skin infections for CMS
and Destiny Pharma. It also provides a valuable additional read across of
comparative activity against MRSA and mupirocin-resistant strains which are a
growing cause of post-surgical infections and is therefore supportive of our
XF-73 nasal gel product."

 

Dr Debra Barker, Interim Chief Executive Officer of Destiny Pharma, said: "The
publication of these new data provides further evidence of the superiority of
XF-73 over the leading standard of care and is highly relevant to our strategy
to advance the product across a range of indications. Working with CMS in this
Innovate UK-backed collaboration has many benefits, not least to our ability
to cross-reference these data, and we look forward to sharing further
progress."

 

Dr Phil Packer, Innovation Lead for AMR at Innovate UK, added: "I am
very excited to see the outputs from this productive international
collaborative project. It demonstrates great commercial potential in the area
of AMR where there is a dire need for novel therapeutics such as XF-73."

 

1.
https://www.coherentmarketinsights.com/market-insight/acute-bacterial-skin-and-skin-structure-infections-absssi-market-1531
(https://www.coherentmarketinsights.com/market-insight/acute-bacterial-skin-and-skin-structure-infections-absssi-market-1531)

 

- END -

For further information, please contact:

 

Destiny Pharma plc
Debra Barker, Interim CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

+44 (0) 20 7250 1446

Destiny@powerscourt-group.com (mailto:Destiny@powerscourt-group.com)

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2 clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COV(TM), a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF drug research projects.

 

For further information on the company, please visit www.destinypharma.com
(http://www.destinypharma.com)

 

About XF-73

XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially
being developed for the prevention of post-surgical staphylococcal infections,
such as methicillin-resistant Staphylococcus aureus (MRSA), which cause
significant complications and increased healthcare costs in the hospital
setting. XF‑73 has been awarded both Qualified Infectious Disease Product
(QIDP) and Fast Track status by the US FDA.

 

Dermal Infections

XF-73 is being developed as a new treatment for serious dermal infections such
as diabetic foot ulcer infections (DFUs) to target a market which is estimated
to be a $0.5 billion global sales opportunity based on the incidence of such
infections, the costs of the associated medical care and a realistic product
pricing of XF-73 in this new market. Driven by the growing number of diabetics
and associated complications such as infected DFUs, this represents a
significant market opportunity for XF-73. It is estimated that twenty-nine
million people in US have a diagnosis of diabetes and of these 13% have active
DFUs.

 

As with all anti-infectives, AMR is also a concern within this market. There
is no dominant treatment for DFUs, and specialist physicians are therefore
working to find better treatment options, including topical formulations. In
addition, the target product profile of XF-73 tested favourably with dermal
clinicians looking for better treatments for the smaller market for
burns/wound infections and venous leg ulcers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKDBPKBKDCON